Hypothalamo-pituitary-adrenocortical dysfunction contributes to morbidity and mortality in a high proportion of patients with sepsis. Here, we provide new insights into the underlying adrenal pathology. Using a murine model of endotoxemia (LPS injection), we demonstrate that adrenal insufficiency is triggered early in the disease. LPS induced a local inflammatory response in the adrenal gland within 4 hours of administration, coupled with increased expression of mRNAs for annexin A1 (AnxA1) and the formyl peptide receptors [(Fprs) 1, 2, and 3], a loss of lipid droplets in cortical cells (index of availability of cholesterol, the substrate for steroidogenesis), and a failure to mount a steroidogenic response to ACTH.
UNREGULATED INFLAMMATION IS AN UNDERLYING component of countless pathologies, such as cardiovascular disease, stroke, and sepsis (1, 2) . Sepsis is 1 of the 10 leading causes of death in the United States (3) and, as such, continues to be a leading clinical problem. Indeed, an important factor in morbidity and mortality caused by sepsis is the systemic inflammatory response syndrome, which, at the cellular level, involves acute activation of leukocytes (4) and an associated cytokine storm (5) . However, therapies that oppose the actions of cytokines or other more specific components of the inflammatory cascade have not been effective in reducing the mortality rate in patients with sepsis. Approximately, over half the cases of sepsis are due to gram-negative bacteria (6) . Endotoxin (LPS), a key cell wall component of gram-negative bacteria, is released upon bacterial lysis. By interacting with receptors, such as monocyte/macrophage CD14 and TLR4, it induces inflammatory mediators, for instance cytokines (e.g., TNF-a) and eicosanoids.
Treating sepsis requires early antimicrobial therapy, hemodynamic management, and consideration of adjunctive therapies (such as hydrocortisone) (7) . The value of glucocorticoid (GC) treatment (high or low dose) is still unclear, with reports of both a beneficial and negative outcomes in patients with septic shock (8, 9) . However, evidence of adrenal insufficiency in sepsis is associated with poor prognosis (9, 10) , with 50-60% of patients demonstrating impaired cortisol responses to exogenous corticotrophin or metyrapone (10) (11) (12) . In support of these findings, Polito et al. (13) described pathologic changes in the adrenal cortex both in patients who died of septic shock and in mice 5 d after the induction of endotoxemia by cecal ligation or incremental dosage of LPS, although the morphologic lesions could not be correlated with deficiencies in basal or ACTH-stimulated cortisol release.
GCs regulate a variety of metabolic, cardiovascular, behavioral, immunologic, and homeostatic mechanisms (14) . Studies in experimental animals have shown that LPS (used to model infection) causes a marked increase in the release of GCs, which, by virtue of their powerful antiinflammatory actions, serve to restrain innate immune response (15) . A similar response occurs in humans, and in the middle of the last century, LPS was used clinically as a test of pituitary ACTH reserve. The initial adrenocortical response to LPS is mediated by proinflammatory cytokines, which stimulate afferent pathways to the hypothalamus and thereby trigger the release of corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) (16, 17) . In addition, LPS exerts direct actions on the anterior pituitary gland and adrenal cortex, which further enhance the release of ACTH and corticosterone (CORT) (18, 19) . However, when LPS is given repeatedly, tolerance develops within the hypothalamo-pituitary-adrenocortical (HPA) axis, and the GC response is thus blunted, partly because the cytokine drive to the hypothalamus is attenuated but also because the negative feedback effects of GCs are enhanced (20) . Studies in mice have revealed significant effects at the adrenal level, with alterations in adrenocortical morphology 5 days after the induction of endotoxemia by cecal ligation or incremental dosage of bacterial LPS (13) , whereas in the rat, the sensitivity of the adrenal cortex to ACTH is impaired (21) .
GCs exert their negative feedback actions at several levels in the brain-HPA axis acting via both genomic and nongenomic mechanisms. Data from our laboratory have identified an important, and novel, role for the GCregulated, 37 kDa protein, annexin A1 [AnxA1; reviewed in (22) ], in the underlying adrenal pathology associated with sepsis. AnxA1 is a Ca 2+ and phospholipid binding protein, which contributes to the anti-inflammatory actions of steroids (23) and powerfully inhibits leukocyte infiltration in a variety of vascular beds (2) . AnxA1 is expressed in the hippocampus (an important site of GC feedback), the hypothalamus, anterior pituitary gland, and adrenal gland where in vivo and in vitro studies have shown that it attenuates the release of CRH/AVP, ACTH, and CORT (22, 24) and is particularly important in modulating the HPA responses to inflammatory stress (25) . Deletion of the AnxA1 gene is associated with exacerbated inflammatory responses (26, 27) .
The actions of AnxA1 within the host defense system are mediated, at least in part, via formyl peptide receptors (FPRs), a family of membrane-bound GPCRs originally identified as targets for bacterial formylated peptides but now known to recognize a variety of endogenous peptide and lipid ligands (e.g., AnxA1, lipoxin A 4 , and b-amyloid) (27) (28) (29) . In humans, 3 family members have been identified and designated: FPR1, formyl peptide receptor 2 (FPR2/ALX), and FPR3 (30) . The FPR family is expanded in mice, but not all members encode functional receptors: the 3 principal members are Fpr1 (human FPR1 ortholog), Fpr2, and Fpr3, which together are broadly comparable to FPR2/ALX (31) . Fpr1, Fpr2, and Fpr3 are all expressed within the murine HPA axis, and functional studies suggest that Fpr2 and/or Fpr3 may mediate the regulatory effects of AnxA1 hormone secretion (32, 33) .
The overall objective of this study was to further explore the roles of AnxA1 and the FPRs in mediating the adrenal responses to LPS in the mouse. Our data show that LPS induces a period of adrenal insufficiency within 4 hours of administration, characterized by impairment of the steroidogenic response to ACTH, depletion of lipid droplets in the cortex, and a local inflammatory response with infiltration of leukocytes into both the cortex and the medulla. These changes were accompanied by increases in AnxA1, Fpr1, Fpr2, and Fpr3 expression in adrenal and other parts of the HPA axis. The depletion of lipid droplets is dependent on AnxA1 and Fpr2/3, whereas circulating leukocytes underpin the local inflammatory response and the up-regulation of AnxA1, Fpr1, and Fpr3, but not Fpr2. These data show for the first time that potentially harmful effects of LPS on adrenal function emerge within hours of exposure to the toxin, and suggest that both AnxA1 and FPRs contribute to the underlying pathology.
MATERIALS AND METHODS

Animals
All studies were performed on adult male mice weighing [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ) expressing green fluorescent protein as a reporter gene (2, 27) were also bred on site. Because the Fpr2/ 3 2/2 strain was newly developed and backcrossed against C57Bl/6 mice for .6 generations, heterozygotes were mated to generate Fpr2/3 +/+ mice and Fpr2/3 2/2 littermates, which served as controls. All animals were genotyped by PCR. The mice were maintained on a standard chow pellet diet with tap water ad libitum using a 12-hour light-dark cycle, in which the temperature was maintained at 21-23°C. Animals were handled for at least 5 days before use. The studies were performed under license in accordance with the UK Animals (Scientific Procedures) Act, 1986, the Italian national legislation (DL 116/92), and European Directive 86/609.
In vivo protocols
Induction of systemic inflammation using LPS C57BL/6 mice, AnxA1 mice, and Fpr2/3 +/+ and Fpr2/3 2/2 mice were treated intraperitoneally with LPS (Escherichia coli serotype O111:B4, 500 mg/kg i.p., 2.5 ml/kg; Sigma-Aldrich, Dorset, United Kingdom) or a corresponding volume of the sterile saline vehicle (2.5 ml/kg i.p. /ml). Experiments were also performed 48 hours after the second injection.
Collection of blood and tissues
Blood was collected from terminally anesthetized mice (pentobarbital sodium, 5 mg/kg, 200 mg/ml i.p.; Merial Animal Health Limited, Cambridge, United Kingdom) by cardiac puncture; plasma and serum were separated and stored at 220°C for analysis. Tissues for quantitative PCR (qPCR) analysis and histology were collected following perfusion of terminally anesthetized mice with sterile saline (n = 6 per group per time point). Tissues (hippocampus, hypothalamus, pituitary and adrenal glands, spleen, and thymus) were either 1) placed in RNase-free Eppendorf tubes with RNAlater (Ambion, Cambridge, United Kingdom) for qPCR analysis, maintained overnight at 4°C, and stored at 280°C, or 2) stored in 10% neutral buffered formalin (Sigma-Aldrich) at room temperature for histology.
Incubation of adrenal cells in vitro
WT mice (n = 15 per group) were killed by CO 2 asphyxiation and cervical dislocation 4 hours after injection of LPS or saline. The adrenal glands were removed and the cells separated as described previously with collagenase and trituration (18) . Aliquots of the dispersed cells (1 3 10 6 cells/ml suspended in Earle's Balanced Salt Solution) were incubated with or without ACTH (0.001-10 mM; Sigma-Aldrich) for 2 hours at 37°C. The medium was collected and stored at 280°C for CORT determination. Cell viability, assessed by the trypan blue exclusion test at the end of the incubation, was .95%.
Biochemical analyses
Analysis of CORT and cytokines CORT was determined in serum (n = 6 per group) and in medium collected from the dispersed adrenal cells by an enzyme immunoassay (EIA) (catalog number AC-14F1; IDS, Tyne & Wear, United Kingdom). DuoSet ELISA Development Kits (R&D Systems, Minneapolis, MN, USA) were used to determine IL-1a (DY400), IL-1b (DY401), IL-6 (catalog number DY406), and TNFa (DY410) in plasma samples. Luminex xMap immunoassay (Life Technologies, Carlsbad, CA, USA) was used for simultaneous analysis of TNF-a, IL-1b, IL-6, IL-10, IL-4, VEGF, RANTES, INF-g, IL-17, and eotaxin (catalog number MPXMCYTO-70K-10; EMD Millipore, Billerica, MA, USA).
qPCR
Probes and primers (Applied Biosystems, Cambridge, United Kingdom) were designed from the mRNA sequences on PubMed for AnxA1, Fpr1, Fpr2, and Fpr3 and checked for homology and specificity ( Table 1) . Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), b-actin, b-microglobulin, or 18S RNA was selected as endogenous controls. RNA isolation from samples of hippocampus, hypothalamus, pituitary and adrenal glands, and spleen was performed using reagents from the SV Total RNA Isolation System (Promega, Southampton, United Kingdom). Because RNA yield from the pituitary gland was low, RNA concentrations were increased using a technique based on isothermal RNA amplification (34) and reagents supplied by Invitrogen (catalog number L1016-01; Life Technologies). RNA was quantified by photometric analysis, qualified using electrophoresis (Agilent Bioanalyzer; Agilent Technologies, Hertfordshire, United Kingdom), and reverse transcribed into cDNA (Invitrogen, Life Technologies).
For each mRNA of interest, primers and probes were prepared at optimized concentrations as specified in Table 1 . For each PCR, 5 ml primer/probe mix, 15 ml TaqMan Master Mix (Life Technologies), 5 ml molecular grade water, and 5 ml sample cDNA were added to each well of a 96-well plate prior to quantitative RT-PCR (qRT-PCR). An interplate control was used where 1 cDNA was run across all plates to monitor for plate variability (not used for normalization) with primers and a probe for 18S RNA (Applied Biosystems). Plates were placed in a 7900HT Fast RealTime PCR System (Applied Biosystems) using an automated loader (Zymark Twister Microplate Handler; Zymark Corporation, Hopkinton, MA, USA). Samples were completed at default running conditions: 1) 50°C for 2 minutes, and 2) 95°C for 10 minutes, 95°C for 15 seconds, and 60°C for 1 minute for 40 cycles. [cycle threshold (Ct)] values were exported as tab-delimited text files for each plate for downstream analysis. Quantification of mRNA was done using a pool of 5 mg RNA that was reverse transcribed to cDNA from the spleen, and assigned an arbitrary copy number of 1 3 10 7 copies/ml, and a range of concentrations was prepared from this stock. The number of copies for all targets of interest, including endogenous controls, was calculated manually based on the log number of copies versus Ct number as calculated by the standard curve. Adjusted means, copy numbers and group mean fold changes in gene expression for each gene, were derived in relation to the control group data, and reported as means 6 SEM of n number of samples per group using TaqMan Toolkit (Brian Bond, GlaxoSmithKline R&D, Stevenage, United Kingdom), specifically designed for qPCR, and is a collection of univariate and multivariate statistical routines for the analysis of data from TaqMan fluorogenic probes.
qRT-PCR for TLR2, TLR4, myeloid differentiation primary response gene 88, and lymphocyte antigen 96 mRNA
Real-time qRT-PCR was employed to measure the expression of TLR2, TLR4, myeloid differentiation primary response gene 88 (MyD-88), and lymphocyte antigen 96 (Ly96) mRNA in adrenal samples from mice treated with LPS or saline as detailed above. qRT-PCR was performed following the manufacturer's instructions using a QuantiFast SYBR Green 1-step RT-PCR kit (Qiagen, Manchester, United Kingdom) with QuantiTect primer assays, containing forward and reverse primers for TLR2, TLR4, MyD-88, Ly96, or GAPDH (Qiagen). Reactions containing 50 ng of template RNA were run using an MX3000P Real-Time Cycler (Stratagene, La Jolla, CA, USA) under the following cycler conditions: reverse transcription at 50°C for 10 minutes, activation at 95°C for 5 minutes, then 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds for denaturation and combined annealing/extension. Fluorescence data collection was performed during the annealing/extension phase, and dissociation curves were performed at the end of each reaction, confirming the presence of a single PCR product per reaction. RNA levels were normalized to the expression of GAPDH for each sample to adjust for uncontrolled variability between samples. Data analysis was performed using the comparative CT method, as described previously (2), and RNA levels were expressed as a fold change compared to the saline baseline group.
Histology
Sections (3 mm) were cut from paraffin-embedded tissues [brain (cerebellum including medulla, cerebrum, and midbrain), spleen, thymus, and pituitary and adrenal glands (paired)] from all animals (n = 6 per group) using a microtome, stained with hematoxylin and eosin (H&E), and evaluated under a light microscope. The sections were checked for the quality of staining and to ensure a representative sample of each tissue was present. Slides were initially read blind, and a record of abnormalities with a grade or score to indicate the severity of the finding (e.g., minimal, mild, slight, moderate, or severe) was made. The slides were unblinded and peer reviewed by a veterinary pathologist to confirm the validity of the work. For differential staining of neutrophils and eosinophils in the adrenal gland, the H&E-staining protocol was modified by including acetic acid (;2-3 drops per 200 ml; Sigma-Aldrich) in the eosin solution to enhance the eosinophilic appearance of PMNs.
Statistical analysis
Gene expression data derived from qPCR were analyzed by ANOVA and post hoc Dunnett's test. GAPDH, b-2 microglobulin (b-2M), or b-actin expression data were used as the covariant for data analysis (endogenous control gene). The covariance efficiency factor was also assessed for each endogenous control (covariate) to ensure that there were no effects of treatment on the endogenous controls. Cytokine and CORT values are expressed as the means 6 SEM of the number of samples (n) per group and analyzed by 1-or 2-way ANOVA with Dunnett's or Bonferroni post hoc test, respectively. Student's t test was used to analyze data from the PMN depletion studies. In all cases, a value of P , 0.05 was considered significant.
RESULTS
Effect of LPS on serum cytokines and CORT release in WT mice
Intraperitoneal LPS triggered an inflammatory response in WT mice, characterized by marked changes in the plasma cytokine profile and increased CORT release (Fig.  1A, B) . Significant increases in the plasma concentrations of TNF-a (P , 0.01), IL-1a (P , 0.05), IL-1b (P , 0.01), and IL-6 (P , 0.01) were observed 2 hours after injection of LPS ( Fig. 1) , but not at 4 or 24 hours. IL-10 (P , 0.01) and RANTES (P , 0.01) were both increased 2 and 4 hours after injection of LPS, but no changes were seen in IL-4, IL-17, VEGF, or eotaxin (data not shown). Serum CORT was raised 2 and 4 hours after injection of LPS (P , 0.01; Fig.  1B ). In vitro, adrenal cells removed from saline-treated control mice responded to ACTH 1-24 (0.001-10 mM) with concentrated-related increases in CORT release (Fig. 1C) . By contrast, adrenal cells from mice treated 4 hours with LPS prior to autopsy were unresponsive to ACTH in vitro and failed to release CORT at any concentration of the peptide tested.
Effects of LPS on gene expression in WT mice
Expression of mRNAs for murine Fpr1, Fpr2, Fpr3, and AnxA1 and the endogenous control genes (GAPDH, b-2M, and b-actin) in the brain, pituitary and adrenal glands, and spleen was assessed 2, 4, 8, and 24 hours after treatment with LPS or saline. Pronounced, highly significant increases in Fpr1, Fpr2, and Fpr3 mRNA expression were evident in the adrenal gland 2, 4, and 8 hours after the injection of LPS (P , 0.01 vs. timematched saline controls), but not at 24 hours ( Fig. 2A-C) . Significant, but less pronounced, increases in AnxA1 mRNA were also evident 2 hours (P , 0.01) and 4 hours (P , 0.05) after LPS (Fig. 2D) . LPS also caused an increase in MyD-88 and TLR2, but not Ly96 or TLR4, expression in the adrenal gland (Supplemental Fig. S1 ). In the pituitary gland, Fpr1 and Fpr2 mRNAs were increased 2 and 4 hours after injection of LPS (P , 0.01 vs. time-matched saline control), whereas increases in Fpr3 mRNAs (P , 0.01) were seen after 2 hours only ( Fig.  2E-H) . LPS also increased expression of Fpr1, Fpr2, and Fpr3, but not AnxA1, mRNAs in the spleen 4 hours after the injection (P , 0.01 vs. controls; Supplemental Fig. S2 ).
By contrast, no changes in the expression of Fpr1, Fpr2, Fpr3, or AnxA1 were seen in the hippocampus or hypothalamus of LPS-treated mice at any time point studied (data not shown). These data demonstrate, for the first time, the LPS-induced time-dependent increases in the expression of AnxA1 and Fprs in endocrine tissues (with the exception of the hypothalamus) in vivo.
Effects of LPS on the morphology of the adrenal gland and spleen
To determine whether the changes in gene expression were associated with morphological changes in the tissue, brain, pituitary, adrenal gland, and spleen were examined histologically 4 hours (as this produced the greatest response in the tissues examined) after injection of LPS or saline. In the adrenal gland, LPS caused a pronounced reduction in vacuolation (an index of lipid droplets removed upon fixation) in the cortical steroidogenic cells versus the saline controls (Fig. 3A, B and Table 2 ). It also triggered infiltration of inflammatory cells into the cortex, medulla, and vascular lumen (Table 2 ). The infiltrating cells were predominantly eosinophilic PMNs, with occasional monocytes and neutrophilic PMNs (Fig. 4) . In the spleen, LPS increased the incidence of lymphoid cell apoptosis (pyknotic nuclei with apoptotic bodies) and extramedullary erythropoiesis (Tables 2 and 3) . By contrast, no morphologic changes were observed in the pituitary gland or brain of LPS-treated mice.
Effects of AnxA1 and Fpr2/3 gene deletion on the histologic responses to LPS
To explore the potential role of AnxA1 or Fpr2/3 in mediating the LPS-induced morphologic histologic changes, parallel studies were performed in Fpr2/3 2/2 and AnxA1 2/2 mice. The reduction in vacuolation in the adrenal cortex that was seen in WT mice following administration of LPS was not apparent in either AnxA1 2/2 (Table 2 ) or a limited number of Fpr2/3 2/2 mice (Table 3) . By contrast, the LPS-induced infiltration of inflammatory cells in the adrenal glands of Fpr2/3 2/2 and AnxA1 2/2 mice was indistinguishable from that observed in the corresponding WT controls (Tables 2 and 3 ). There were no differences seen in the spleen between saline or LPS-treated Fpr2/3 2/2 and AnxA1 2/2 mice. No microscopic changes were detected in the brain or pituitary gland of Fpr2/3 2/2 and AnxA1 2/2 mice 4 hours after treatment with LPS (Tables 1 and 2 ).
Effects of PMN depletion of the adrenal responses to LPS
The results described demonstrate the LPS-induced adrenal inflammatory responses. Our next experiment aimed to determine whether the adrenal responses to LPS were secondary to the infiltration of leukocytes, by making mice neutropenic, via administration of an anti-PMN serum.
The LPS-induced infiltration of leukocytes into the adrenal gland was reduced in PMN-depleted mice Figure 1 . Heightened inflammatory response to LPS on serum cytokines and CORT release in WT mice. Either plasma was collected by cardiac puncture for up to 24 hours after administration of LPS (500 mg/kg) or saline (SAL; both at 2.5 ml/kg i.p.) for the analysis of (A) TNF-a, IL-1a, IL-1b, and IL-6 by ELISA (at 0, 2, 4, and 24 hours), or serum was collected 2 or 4 hours after administration of LPS (500 mg/kg) or saline (both at 2.5 ml/kg i.p.) for the analysis of (B) serum CORT via EIA. C) In a separate set of experiments, mice adrenal glands were removed, the cells were separated and incubated with varying concentrations of ACTH 1-24 medium collected, and CORT levels were determined using EIA. Values are the means 6 SEM (n = 3-5 wells per concentration; adrenal glands were collected from 15 WT mice per group).
versus IgG-treated controls (Table 4) . Thus, LPS failed to cause inflammatory cell infiltration in the adrenal cortex or medulla in 2 of the 6 PMN-depleted animals studied, whereas in the remaining 4 animals, the cell infiltration was minimal (and in 1 animal, only detectable in 1 of the 2 adrenal glands). Again, the invading cells were predominantly eosinophilic PMNs, with occasional monocytes and neutrophilic PMNs spread throughout the gland with sporadic lymphocytes in the lumen of the medullary vessels. However, the decrease in vacuolation induced by LPS in the cortical cells was unaffected by PMN depletion (Table 4) . PMN depletion also failed to modify the changes in splenic morphology induced by LPS (data not shown).
Significant (P , 0.05) increases in Fpr1, Fpr2, and Fpr3 (adrenal only) mRNAs were evident in the adrenal glands and spleen of control (IgG-treated) mice 4 hours after injection of LPS. By contrast, LPS had no effect on the expression of the Fpr1, Fpr3, or AnxA1 mRNAs in the adrenal gland of neutropenic mice. However, as observed in mice treated with the control serum, LPS increased Fpr2 expression in neutropenic mice (P , 0.01; Fig. 5) . Similarly, LPS increased expression of Fpr2 mRNA in the spleen of PMN-depleted mice (P , 0.05 vs. time-matched saline controls) but failed to influence the expression of Fpr1, Fpr3, or AnxA1 (data not shown).
PMN depletion did not affect the magnitude of the increases in circulating CORT and cytokines (TNF-a, IL-6, IL-10, and RANTES) observed 4 hours after treatment with LPS (P . 0.05 PMN-depleted versus IgG-treated controls). However, the LPS-stimulated increase in plasma IL-1b was exacerbated by PMN depletion (P , 0.01 versus IgG-treated control). Furthermore, and in contrast to untreated WT mice, LPS increased plasma IL-10 in both IgG-and anti-PMN-treated mice but had a more pronounced effect in the PMN-depleted group (2.2-fold; P , 0.01 vs. IgG treatment).
DISCUSSION
Sepsis is one of the most common causes of death in hospitalized patients, accounting for 9.3% of overall deaths in the United States annually (2, 35) , despite advances in Figure 2 . Time-dependent effects of LPS on Fpr1, Fpr2, Fpr3, and AnxA1 mRNA expression in the adrenal and pituitary glands. LPS (500 mg/kg i.p.) or saline (both at 2.5 ml/kg i.p.) was administered to WT mice, and the adrenal (A-D) and pituitary (E-H) glands were removed at various time points. mRNAs for (A and E) Fpr1, (B and F) Fpr2, (C and G) Fpr3, and (D and H) AnxA1 were quantified by qPCR (n = 6 animals per group per time point; mean adjusted to GAPDH 6 SEM). *P , 0.05 and **P , 0.01 vs. time-matched saline control.
intensive care treatment and antibiotic development. HPAaxis dysfunction occurs in a high proportion of patients with sepsis and may contribute to the morbidity and mortality associated with the disease (10, 11). Here, using an animal model of endotoxemia, we reveal novel evidence to suggest that this dysfunction is triggered at an early stage of the disease, and also demonstrate the importance of the AnxA1/FPR2/ALX pathway as an effector of this event. Our data show that within 4 hours of administration, LPS initiates a local inflammatory response in the adrenal gland, which is coupled with a loss of lipid droplets in the cortical cells and a concomitant failure to mount a steroidogenic response to ACTH. The depletion of lipid droplets is dependent on AnxA1 and Fpr2/3, whereas circulating leukocytes underpin the local inflammatory response and the up-regulation of AnxA1, Fpr1, and Fpr3, but not Fpr2. Together, these results not only reveal an important role of the AnxA1/FPR2/ALX system in contributing to the pathologic changes in the adrenal gland but also provide evidence of a novel and important interface between the immune and endocrine systems.
Sepsis is associated with an excessive production of cytokines (including TNF-a, IL-1b, and IL-6), as well as activation of the complement and coagulation cascades (36) following activation of immune cells by endotoxin and other pathogen components. In our model, LPS treatment produced a marked inflammatory response over a 24-hour period. LPS-induced peritonitis is normally accompanied by a systemic inflammatory response and is, thus, sometimes used as a model of sepsis. Here, we confirm reports that LPS (500 mg/kg i.p.) induces increases in proinflammatory cytokines (TNF-a, IL-1a, IL-1b, IL-6, and RANTES) and CORT followed by a period of adrenal insufficiency. The magnitude of the initial inflammatory response was however modest, with most cytokines returning to baseline levels within 4 hours, and was more than likely related to the dose of LPS used. In addition, the release of TNF-a may have been tempered by the rise in the antiinflammatory cytokine, IL-10 (37).
LPS activates the TLR group of pattern recognition receptors, including both TLR2 and TLR4 (38) , which subsequently activates additional signaling pathways through the adaptor protein MyD-88 (2). The up-regulation of TLR2 in the adrenal gene expression may therefore be closely linked to the increased expression of MyD-88. Indeed, the increase in adrenal gene expression of TLR2 and the unchanged expression of TLR4 mRNA in LPS-treated animals are similar to that observed in both the liver (39) and hepatic circulation (40) . Ly96 is a binding protein that is required for the function of TLR4. A number of studies have demonstrated the TLR4/Ly96 complex as the major signaling receptor for LPS in mammals (41, 42) . Therefore, the fact that both Ly96 mRNA and TLR4 levels in mouse adrenal gland do not change post-LPS challenge indicates that TLR4 is not involved in mediating the adrenal responses to sepsis.
LPS caused marked increases in the expression of Fpr1, Fpr2, Fpr3, and AnxA1 mRNAs in the pituitary and adrenal glands and spleen, but not in the brain (hypothalamus or hippocampus). These findings concur with reports that endotoxin 1) increases AnxA1 expression in a murine pituitary cell line (43) and in murine leukocytes and epithelial cells in vivo (44), and 2) induces expression and stabilization of Fpr1 mRNA in murine leukocytes (45) and up-regulates human FPR2/ALX in human monocytes and macrophages (46) . To the best of our knowledge, however, this is the first report of LPSinduced time-dependent increases in the expression of AnxA1 and FPRs in endocrine tissues in vivo. Given the well-documented inhibitory effects of AnxA1 on the secretion of ACTH [reviewed in (22) ] and CORT (24) , the LPS-induced changes in gene expression reported here may well contribute to the attenuation of the initial HPA response to the toxin. The failure of LPS to modify FPR/ AnxA1 expression in the brain was surprising, given that LPS induces cytokine expression in the brain (47) and that AnxA1 and the FPRs are up-regulated in the brain by local tissue injury (26, 48) . Initially, we attributed our cerebral findings to the dose of LPS, but we later found that central administration of LPS (50 mg/kg intracerebroventricularly) also failed to modify AnxA1/FPR expression in the hippocampus or hypothalamus, although it increased expression of these genes in the pituitary and adrenal glands.
Leukocyte infiltration of the adrenal gland
In addition to increasing AnxA1/FPR expression, LPS induced a local inflammatory response in adrenal gland within 4 hours of administration, characterized by leukocytic infiltration (predominantly eosinophilic) of the cortex and medulla. Eosinophils are generally considered to be the predominant inflammatory cells associated with allergic asthma and parasitic infections. However, in line with our findings, these multifunctional leukocytes, which are recruited from the circulation into inflammatory foci, are now considered to play important roles in both innate and adaptive immunity (49) . By contrast, although mild-tomoderate lymphoid necrosis and apoptosis occurred in the thymus and spleen, respectively, there was no evidence of inflammatory cell infiltration in the other tissues we examined (brain, pituitary gland, spleen, or thymus). Previous studies have described PMN infiltration in the rat adrenal medullary sinusoids 24 hours after LPS treatment, together with necrosis in the adrenal medulla, spleen, and thymus (50); in addition, inflammatory infiltrates, necrosis, and hemorrhage have been reported postmortem in the adrenal cortex (zona fasciculata) of patients with septic shock (13) . To the best of our knowledge, this is the first report of a rapid inflammatory response in the adrenal glands, evident within 4 hours of LPS administration, suggesting that the adrenal gland may be an early target organ during infection.
AnxA1 and FPRs are expressed in abundance by leukocytes (31) and play an important role in modulating leukocyte (particularly neutrophil) migration from the blood in conditions of inflammation (e.g., following an LPS challenge) (2, 51) . In light of these findings, we predicted that the LPS-induced leukocytic infiltration of the adrenal gland would be exaggerated in AnxA1 2/2 and LPS (500 mg/kg) or saline (both at 2.5 ml/kg i.p.) was administered to WT and ANXA1 2/2 mice. Tissues were removed, fixed in 10% neutral buffered formalin, embedded in paraffin wax, and sections were cut (3 mm) and stained with H&E for evaluation by light microscopy (n = 6 animals per group). Values represent the number of animals in which the finding was observed. , and (B) shows an eosinophil (Eo) and neutrophil (Ne) (indicated by arrows), both with a lobular nucleus; however, eosinophils were frequently seen unlike neutrophils and monocytes that were only occasional seen (360). In saline-treated mice, no inflammatory cell infiltration was seen in any animal. Images are representative of n = 6 animals per group.
Fpr2/3 2/2 mice. However, this was not the case despite reports of both strains exhibiting enhanced leukocyte migration across other vascular beds during inflammation (26) , suggesting some degree of tissue selectivity in the response. Furthermore, although AnxA1 has proapoptotic properties (43), the incidence of LPS-induced apoptosis in the spleen and thymus was also unaffected by deletion of AnxA1. It may be that these mice develop an effective compensatory mechanism or that the mechanisms governing leukocyte infiltration in the adrenal gland differ from those described in other tissues. Further experiments are required to elucidate these findings.
Mice were made neutropenic, using anti-PMN serum (52) , in order to explore whether the infiltrating leukocytes were responsible for the increases in AnxA1 and FPR gene expression initiated by LPS. Treatment with anti-PMN serum blocked LPS-induced infiltration of leukocytes and the concomitant increases in AnxA1, Fpr1, and Fpr3 expression in the adrenal gland, suggesting that the altered expression of these genes is secondary to the inflammatory cell infiltration and, indeed, that the cells may themselves may be the source of the newly synthesized mRNAs. Alternatively, these cells may release other factors (e.g., cytokines), which upregulate AnxA1, Fpr1, and Fpr3 expression in resident adrenal cells. By contrast, PMN depletion did not prevent the LPS-induced up-regulation of Fpr2 in the adrenal gland, suggesting that expression of this gene occurs within resident adrenal cells and is independent of leukocyte infiltration. Interestingly, the pattern of gene expression in the spleen of PMN-depleted mice paralleled that in the adrenal glands, suggesting that similar regulatory mechanisms exist in the 2 very different tissues.
Although LPS initially stimulates steroidogenesis, in part through direct actions on the adrenal gland (44), our results show that within 4 hours of treatment, the steroidogenic capacity of the gland is grossly impaired due to a loss of the cholesterol substrate (as indexed by the loss of lipid droplets) and failure of the cells to respond to ACTH. Similar findings have been reported in rats 24 hours after LPS treatment (44) . In addition, lipid depletion has been reported in mice 5 days after either cecal ligation or daily injection of increasing doses of LPS (12) and in patients who died of septic shock (13) .
As discussed earlier, the initial steroidogenic response to LPS is affected by increased secretion of ACTH (16) and by direct action of LPS and proinflammatory cytokines (53, 54) within the adrenal cortex. Several mechanisms may contribute to the subsequent potentially harmful effects of the toxin on the adrenal cells, which lead to a failure of steroidogenesis. First, because AnxA1 suppresses ACTH-driven CORT release and ACTH-null mice show an enhanced steroidogenic response to ACTH (17), LPS-induced increased expression of AnxA1 and its receptors (i.e., Fprs) would be expected to attenuate ACTHinduced steroidogenesis. Second, LPS-induced leukocyte influx would initially provide a further source of proinflammatory cytokines to enhance steroidogenesis, but these cells also produce defensins (corticostatins), which antagonize the actions of ACTH (55) . Third, tolerance develops Fpr2/3 +/+ or Fpr2/3 2/2 mice were treated with LPS (500 mg/kg) or saline (both at 2.5 ml/kg i.p.). Tissues were removed 4 hours later, fixed in 10% neutral buffered formalin, embedded in paraffin wax, and sections were cut at 3 mm and stained with H&E for evaluation by light microscopy (n = 3 animals per group).
a No sample. LPS (500 mg/kg) or saline (both at 2.5 ml/kg i.p.) was administered to PMN-depleted and IgG-treated WT mice. At 4 hours after injection, tissues were removed, fixed in 10% neutral buffered formalin, embedded in paraffin wax, and sections were cut (3 mm) and stained with H&E for evaluation by light microscopy (n = 6 animals per group). PMNs were depleted through pretreatment with an anti-PMN serum (10 ml/kg i.p.) for 2 days prior to injection with LPS. IgGmatched serum controls were also included (10 ml/kg i.p.). Values represent the number of animals in which the finding was observed.
to LPS in the adrenal gland within 24 hours of treatment due to down-regulation of TLR4 (56); in addition, ACTH receptor expression is reduced (57) , and the downstream up-regulation of the steroidogenic enzymes CYP11A1 (the rate-limiting enzyme), HSD3b, and CYP21, but not of steroid acute regulatory protein (StAR) or CYP11B1, is consequently impaired (56) . Interestingly, LPS causes only a small reduction in the ability of dcAMP to increase CORT synthesis and does not affect the response to pregnenolone (55) , suggesting that the loss of functional ACTH receptors is a key factor in the impairment of steroidogenesis. Furthermore, in contrast to the findings in vitro (56), LPS up-regulates StAR expression in mice in vivo (58) .
Finally, and most importantly, whereas adrenal cells have the capacity for de novo cholesterol synthesis, the principal source of the steroid is through uptake of cholesterol ester from the HDL-cholesterol ester complex-a process that is affected by scavenger receptor class B, type 1 (SR-B1), a cell surface glycoprotein [reviewed in (59) ]. Free cholesterol is then liberated by cytoplasmic lipases and transported into the mitochondria by StAR. Not surprisingly, cholesterol ester accumulation in the adrenal gland is impaired in SR-B1-null mice as too is the steroidogenic response to acute stress [e.g., LPS (60)]. Our novel finding that the LPSinduced loss of lipid droplets is prevented by deletion of the genes for either AnxA1 or Fpr2/3 provides potentially important evidence for a role for these genes in the manifestation of this pathologic response within the adrenal gland. The mechanism through which they act is unknown and appears to be unrelated to the local inflammatory response triggered by LPS because leukocyte infiltration was unaffected by deletion of AnxA1 or Fpr2/3. Furthermore, PMN depletion failed to influence the loss of lipid droplets or the induction of Fpr2 caused by LPS, although the increases in AnxA1, Fpr1, and Fpr3 were prevented. Although AnxA1 has been linked to cholesterol synthesis, the potential role of the ANXA1/FPR system in the regulation of cholesterol transport has not been explored. Circulating total cholesterol levels are unaffected by deletion of AnxA1 or Fpr2/3 (27, 33) . However, AnxA1 2/2 mice are more sensitive to the steroidogenic actions of ACTH (24), perhaps because they accumulate cholesterol ester more effectively; furthermore, ANXA1 Ac2-26 inhibits CORT release in vitro. It is not yet known which Fpr subtype is responsible for the inhibitory effect of this nonselective peptide on steroidogenesis. However, because Fpr2/3 gene deletion prevents the LPS-induced lipid depletion in adrenocortical cells and the LPSinduced loss of lipid droplets in PMN-depleted mice is coupled with increased expression of Fpr2, but not Fpr1 or Fpr3, it is possible that Fpr2 plays a critical role in the depletion of cholesterol ester stores. Hence, blockade of Fpr2 may provide a new approach to maintaining adrenal function in endotoxemia. This concept merits further investigation.
In summary, our data (summarized in Fig. 6 ) clearly demonstrate that primary adrenal insufficiency develops within a few hours of initial activation of the HPA axis in murine endotoxemia. The adrenal pathology is characterized by local inflammation, a profound loss of lipid droplets from the cortical cells, and a concomitant failure of these cells to mount a steroidogenic response to ACTH. The infiltrating leukocytes are responsible for the increased expression of AnxA1, which may serve to counter the inflammatory response, and for the up-regulation of Fpr1 and Fpr2; they may also release other factors that modulate steroidogenesis, adrenal medullary hormone release, and other facets of adrenal function, such as blood flow and cell turnover. Importantly, we report for the first time that the LPS-induced loss of lipid droplets, and associated failure of steroidogenesis, is prevented by deletion of the genes for AnxA1 or Fpr2/3 and suggesting that Fpr2/3 may be critically important in this regard. Overall, the results presented here indicate that these genes have a critical role in the regulation of cholesterol ester storage Figure 5 . Effect of LPS on the expression of Fpr1, Fpr2, Fpr3, and AnxA1 mRNA in adrenal glands from PMN-depleted WT mice. LPS (500 mg/kg) or saline (both at 2.5 ml/kg i.p.) was given to PMN-depleted or IgG-treated WT mice (n = 6 per group), and adrenal glands were removed after 4 hours. (A) Fpr1, (B) Fpr2, (C) Fpr3, and (D) AnxA1 mRNA was quantified by qRT-PCR (means adjusted to b-actin 6 SEM). PMNs were depleted through pretreatment with an anti-PMN serum (10 ml/kg i.p.) for 2 days prior to injection with LPS. IgG-matched serum controls were also included (10 ml/kg i.p.). NS, not significant. *P , 0.05 and **P , 0.01 vs. IgG controls.
in the adrenal gland and that pharmacologic interventions that target the AnxA1/FPR2/ALX pathway will provide a new approach for the maintenance of adrenal steroidogenesis in sepsis. Figure 6 . Schematic overview of the importance of the AnxA1/FPR2/ALX pathway in adrenal steroidogenesis, in sepsis. LPS induces an inflammatory response in the adrenal glands with 4 hours of administration, characterized by (1) leukocyte infiltration [predominantly eosinophilic (Eo)], suggesting that the adrenal gland may be an early target organ during infection. LPS activates (2) TLR2/MyD-88 complex, not TLR4, in the adrenal gland, increasing (3) the expression of Fpr1, Fpr2, Fpr3, and AnxA1. LPS also causes (4) a profound loss of lipid droplets from cortical cells and a concomitant failure of these cells to mount a (5) steroidogenic response to ACTH. LPS-induced loss of lipid droplets, and associated failure of steroidogenesis, is prevented by deletion of the genes for AnxA1 or Fpr2/3, suggesting that Fpr2/3 may be critically important in this regard. Therefore, pharmacologic interventions that target the AnxA1/FPR2/ALX pathway will provide a new approach for the maintenance of adrenal steroidogenesis in sepsis. MyD-88 * *
